These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 32017248)

  • 1. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Kyle Jensen M; LaFleur J; Nelson RE
    Infect Control Hosp Epidemiol; 2015 Apr; 36(4):438-44. PubMed ID: 25782899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection.
    Jiang M; Leung NH; Ip M; You JHS
    PLoS One; 2018; 13(7):e0201539. PubMed ID: 30048534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
    Luo Y; Lucas AL; Grinspan AM
    Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
    Merlo G; Graves N; Brain D; Connelly LB
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
    Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
    Allegretti JR; Axelrad J; Dalal RS; Kelly CR; Grinspan A; Fischer M
    Am J Gastroenterol; 2024 Jul; 119(7):1433-1436. PubMed ID: 38501667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease.
    Cho S; Spencer E; Hirten R; Grinspan A; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):343-347. PubMed ID: 30320666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
    Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF
    Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
    Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
    PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal microbiota transplantation for treatment of refractory or recurrent
    Lan KY; Le PH; Chiu CT; Chen CC; Yeh YM; Cheng HT; Kuo CJ; Chen CL; Chen YC; Yeh PJ; Chiu CH; Chang CJ
    Front Med (Lausanne); 2023; 10():1229148. PubMed ID: 37849493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
    Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
    Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent
    Rokkas T; Gisbert JP; Gasbarrini A; Hold GL; Tilg H; Malfertheiner P; Megraud F; O'Morain C
    United European Gastroenterol J; 2019 Oct; 7(8):1051-1063. PubMed ID: 31662862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
    Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.